Lung and liver sarcoidosis‐like reaction induced by tocilizumab

Lambert, Nicolas; Hansen, Isabelle; El Moussaoui, Majdouline; GIOT, Jean-Baptiste; Vercheval, Christelle; LOMMERS, Emilie; SOMJA, Joan; MOUTSCHEN, Michel; MAQUET, Pierre

doi:10.1111/bcp.14878

Request a copy

Article (Scientific journals)

Lung and liver sarcoidosis‐like reaction induced by tocilizumab

Lambert, Nicolas; Hansen, Isabelle; El Moussaoui, Majdouline et al.

2021 • In British Journal of Clinical Pharmacology

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/259267

DOI
10.1111/bcp.14878

PubMed
33899928

Files (3)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Manuscript with correction FINAL.pdf

Author preprint (119.26 kB)

Request a copy

Annexes

Figure 1 New.png

Publisher postprint (12.25 MB)

Figure 1

Request a copy

Figure 2.png

Publisher postprint (9.62 MB)

Figure 2

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Adverse drug reaction; Monoclonal antibodies; Pharmacovigilance

Abstract :

[en] A drug‐induced sarcoidosis‐like reaction is a systemic granulomatous reaction indistinguishable from sarcoidosis and occurring in temporal relationship with a drug initiation. In this article, we report a patient who developed lung and liver granulomatous lesions following tocilizumab initiation for a giant cell arteritis. Infectious, toxic, neoplastic and inflammatory differential diagnoses were ruled out and lesions regressed after treatment cessation, leading to the diagnosis of tocilizumab induced sarcoidosis‐like reaction. We review the six cases reported so far and emphasize the value of a prompt diagnosis. Finally, we discuss the potential pathophysiological mechanisms underlying this rare reaction, which could help to better understand the pathophysiology of sarcoidosis.

Disciplines :

General & internal medicine

Author, co-author :

Lambert, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Hansen, Isabelle ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

El Moussaoui, Majdouline ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique

GIOT, Jean-Baptiste ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne

Vercheval, Christelle ; Centre Hospitalier Universitaire de Liège - CHU > Département de pharmacie hospitalière > Service de pharmacie clinique

LOMMERS, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

SOMJA, Joan ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Service d'anatomie et cytologie pathologiques

MOUTSCHEN, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne

MAQUET, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Language :

English

Title :

Lung and liver sarcoidosis‐like reaction induced by tocilizumab

Publication date :

26 April 2021

Journal title :

British Journal of Clinical Pharmacology

ISSN :

0306-5251

eISSN :

1365-2125

Publisher :

Blackwell, Oxford, United Kingdom

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://doi.org/10.1111/bcp.14878

Available on ORBi :

since 26 April 2021

Statistics

Number of views

236 (21 by ULiège)

Number of downloads

5 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972-1988.
Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705-714.
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. New Eng J Med. 2017;377(4):317-328.
Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-Induced Sarcoidosis-Like Reactions. Chest. 2018;154(3):664-677.
Nutz A, Pernet C, Combe B, Cohen JD. Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol. 2013;40(10):1773-1774.
Bustamente L, Buscot M, Marquette CH, Roux C. Sarcoidosis and tocilizumab: is there a link? Clin Exp Rheumatol. 2017;35(4):716.
Shono Y, Kamara M, Takeoka S, et al. Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab. J Dermatol. 2018;45(8):e217-e218.
N'guyen Van Thanh dit Bayard J, Glanowski C, Clouzeau A, Bialé L, Banal F, Lechevalier D. Une sarcoïdose sous tocilizumab: à propos d'un cas. Rev Med Interne. 2018;39(10):834.
Del Giorno R, Iodice A, Mangas C, Gabutti L. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. Ther Adv Musculoskel Dis. 2019;12:1-6.
Theodosiou G, Luu H, Svensson Å. Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon. Int J Dermatol. 2020;59(7):888-889.
WHO Pharmacovigilance team. The use of the WHO-UMC system for standardized case causality assessment. https://www.who.int/publications/m/item/WHO-causality-assessment. Accessed February 26, 2021.
Cohen Aubart F, Lhote R, Amoura A, et al. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med. 2020;288(3):356-362.
Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004.
El Jammal T, Jamilloux Y, Gerfaud-Valentin M, Valeyre D, Sève P. Refractory Sarcoidosis: A Review. Ther Clin Risk Manag. 2020;17(16):323-345.
Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59-65.
Broos CE, Hendriks RW, Kool M. T-cell immunology in sarcoidosis: Disruption of a delicate balance between helper and regulatory T-cells. Curr Opin Pulm Med. 2016;22(5):476-483.
Ramstein J, Broos CE, Simpson LJ, et al. IFN-ɣ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells. Am J Respir Crit Care Med. 2016;193(11):1281-1291.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448-455.
Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1(6):510-514.
Bleier JI, Pillarisetty VG, Shah AB, DeMatteo RP. Increased and long-term generation of dendritic cells with reduced function from IL-6 deficient bone marrow. J Immunol. 2004;172(12):7408-7416.
Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest. 2002;122(5):1858-1860.
Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199(2):173-183.
Marzouk S, Hriz H, Jallouli M, Cherif Y, Bahloul Z. Association sarcoïdose et maladie de Horton: à propos d'un cas [Association sarcoidosis and Horton disease: report of a case]. Pan Afr Med J. 2015;20:98
Marcussen N, Lund C. Combined sarcoidosis and disseminated visceral giant cell vasculitis. Pathol Res Pract. 1989;184(3):325-330.
Homolka J, Muller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung. 1993;171(3):173-183.